 AIM ImmunoTech Inc NYSE:AIM revealed that the Netherlands Patent Office Octrooicentrum Nederland has issued Patent No 2027383 - a utility patent - covering Ampligen rintatolimod and other dsRNA products developed by the company for use in the prevention, or treatment of coronavirus COVID-19, with a base patent term extending until 2041. The Ocala, Florida-based immuno-pharma companys RNA product candidate is being developed for globally important cancers, viral diseases and disorders of the immune system. 